A randomized placebo-controlled trial of an NMDA receptor antagonist in sleep-disordered breathing
STEFAN TORVALDSSON
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorLUDGER GROTE
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorYÜKSEL PEKER
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorJAN HEDNER
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorSTEFAN TORVALDSSON
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorLUDGER GROTE
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorYÜKSEL PEKER
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorJAN HEDNER
Sleep Laboratory, Department of Allergology and Pulmonary Medicine, Sahlgrenska University Hospital, Göteborg
Search for more papers by this authorSummary
Hypoxemia is a powerful stimulus of glutamate release in the central nervous system (CNS) and a hallmark phenomenon in sleep disordered breathing (SDB). Glutamate effects that include neuronal damage and apoptosis following hypoxemia and apnea following microinjections in animal models are in part mediated via postjunctional N-methyl-d-aspartate (NMDA) receptors. This was a double blind, randomized, placebo-controlled single dose cross-over study of the NMDA receptor antagonist AR-R15896AR in 15 male patients with moderate to severe SDB. Seven patients received 120 mg and eight patients received 350 mg AR-R15896AR or corresponding placebo (given by 2 h infusion) starting half an hour before estimated sleep onset. AR-R15896AR concentrations were in line with the predicting kinetic model. A standard polysomnographic montage was applied. Repeated plasma samples were obtained in nine patients for analysis of plasma glutamate. Glutamate concentration in plasma did not change overnight and was unrelated to severity of SDB. Overall AHI (apnea–hypopnea index; primary efficacy variable) or investigated oxygen saturation variables were not significantly changed after AR-R15896AR at either dosage level. Side effects were mostly confined to the higher dose level and included vivid dreams, nightmares as well as in two cases mild hallucinations. The previously postulated role of glutamate in SDB could not be confirmed after AR-R15896AR induced NMDA-receptor blockade.
References
- Asyali, M. H., Berry, R. B. and Khoo, M. C. Assessment of closed-loop ventilatory stability in obstructive sleep apnea. IEEE Trans. Biomed. Eng., 2002, 49: 206–216.
- Berry, R. B., Kouchi, K. G., Der, D. E., Dickel, M. J. and Light, R. W. Sleep apnea impairs the arousal response to airway occlusion. Chest, 1996, 109: 1490–1496.
- Brownell, L. G., West, P., Sweatman, P., Acres, J. C. and Kryger, M. H. Protriptyline in obstructive sleep apnea: a double-blind trial. N. Engl. J. Med., 1982, 307: 1037–1042.
- Campbell, I. G., Gustafson, L. M. and Feinberg, I. The competitive NMDA receptor antagonist CPPene stimulates NREM sleep and eating in rats. Neuropsychopharmacology, 2002, 26: 348–357.
- Datta, S., Patterson, E. H. and Spoley, E. E. Excitation of the pedunculopontine tegmental NMDA receptors induces wakefulness and cortical activation in the rat. J. Neurosci. Res., 2001, 66: 109–116.
- Diener, H. C., AlKhedr, A., Busse, O., Hacke, W., Zingmark, P. H., Jonsson, N. and Basun, H. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study. J. Neurol., 2002, 249: 561–568.
- Ferguson, K. A., Ono, T., Lowe, A. A., Keenan, S. P. and Fleetham, J. A. A randomized crossover study of an oral appliance vs nasal-continuous positive airway pressure in the treatment of mild-moderate obstructive sleep apnea. Chest, 1996, 109: 1269–1275.
- Friberg, D., Gazelius, B., Hokfelt, T. and Nordlander, B. Abnormal afferent nerve endings in the soft palatal mucosa of sleep apnoics and habitual snorers. Regul. Pept., 1997, 71: 29–36.
- Gislason, T., Almqvist, M., Eriksson, G., Taube, A. and Boman, G. Prevalence of sleep apnea syndrome among Swedish men – an epidemiological study. J. Clin. Epidemiol., 1988, 41: 571–576.
- Grote, L., Hedner, J., Grunstein, R. and Kraiczi, H. Therapy with nCPAP: incomplete elimination of Sleep Related Breathing Disorder. Eur. Respir. J., 2000, 16: 921–927.
- Grunstein, R. R., Stenlof, K., Hedner, J. and Sjostrom, L. Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int. J. Obes. Relat. Metab. Disord., 1995, 19: 410–418.
- Harris, M. B. and Milsom, W. K. The influence of NMDA receptor-mediated processes on breathing pattern in ground squirrels. Respir. Physiol., 2001, 125: 181–197.
- Hedner, J., Grunstein, R., Eriksson, B. and Ejnell, H. A double-blind, randomized trial of sabeluzole – a putative glutamate antagonist – in obstructive sleep apnea. Sleep, 1996, 19: 287–289.
- Hedner, J., Kraiczi, H., Peker, Y. and Murphy, P. Reduction of sleep-disordered breathing after physostigmine. Am. J. Respir. Crit. Care Med., 2003, 168: 1246–1251.
- Hudgel, D. W., Gordon, E. A., Thanakitcharu, S. and Bruce, E. N. Instability of ventilatory control in patients with obstructive sleep apnea. Am. J. Respir. Crit. Care Med., 1998, 158: 1142–1149.
- Ip, M. S., Lam, B., Ng, M. M., Lam, W. K., Tsang, K. W. and Lam, K. S. Obstructive sleep apnea is independently associated with insulin resistance. Am. J. Respir. Crit. Care Med., 2002, 165: 670–676.
- Kraiczi, H., Hedner, J., Dahlof, P., Ejnell, H. and Carlson, J. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep, 1999, 22: 61–67.
- Kribbs, N. B., Pack, A. I., Kline, L. R., Smith, P. L., Schwartz, A. R., Schubert, N. M., Redline, S., Henry, J. N., Getsy, J. E. and Dinges, D. F. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am. Rev. Respir. Dis., 1993, 147: 887–895.
- Lojander, J., Maasilta, P., Partinen, M., Brander, P. E., Salmi, T. and Lehtonen, H. Nasal-CPAP, surgery, and conservative management for treatment of obstructive sleep apnea syndrome. A randomized study. Chest, 1996, 110: 114–119.
- Loube, D. I., Gay, P. C., Strohl, K. P., Pack, A. I., White, D. P. and Collop, N. A. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients: a consensus statement. Chest, 1999, 115: 863–866.
- Marchenko, V. and Sapru, H. N. Different patterns of respiratory and cardiovascular responses elicited by chemical stimulation of dorsal medulla in the rat. Brain Res., 2000, 857: 99–109.
- McCrimmon, M.M. Glutamate GABA and serotonin in ventilatory control. In: J. A. P. A. Dempsey (ed.) Regulation of breathing. Marcel Dekker Inc., New York, 1995: 151–218.
- McManigle, J. E., Panico, W. H., DaSilva, A. M. and Gillis, R. A. Respiratory effects produced by microinjection of L-glutamate and an uptake inhibitor of L-glutamate into the caudal subretrofacial area of the medulla. Eur. J. Pharmacol., 1995, 280: 257–275.
- Meldrum, B. and Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci., 1990, 11: 379–387.
- Mezzanotte, W. S., Tangel, D. J. and White, D. P. Influence of sleep onset on upper-airway muscle activity in apnea patients versus normal controls. Am. J. Respir. Crit. Care Med., 1996, 153: 1880–1887.
- Palmer, G. C., Cregan, E. F., Bialobok, P., Sydserff, S. G., Hudzik, T. J. and McCarthy, D. J. The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke. Ann. N. Y. Acad. Sci., 1999, 890: 406–420.
- Peker, Y., Kraiczi, H., Hedner, J., Loth, S., Johansson, A. and Bende, M. An independent association between obstructive sleep apnoea and coronary artery disease. Eur. Respir. J., 1999, 14: 179–184.
- Peker, Y., Hedner, J., Kraiczi, H. and Loth, S. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am. J. Respir. Crit. Care Med., 2000, 162: 81–86.
- Radulovacki, M., Pavlovic, S., Rakic, A., Janelidze, M., Shermulis, L. and Carley, D. W. Riluzole suppresses post-sigh, but not spontaneous apnoeas during sleep in rats. J. Pharm. Pharmacol., 2001, 53: 1555–1559.
- Rechtshaffen, A. and Kales, A. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Subjects. NIH Publications No. 204. Public Health Service, US Government Printing Office, Washington, DC, 1968.
- Remmers, J. E., DeGroot, W. J., Sauerland, E. K. and Anch, A. M. Pathogenesis of upper airway occlusion during sleep. J. Appl. Physiol., 1978, 44: 931–938.
- Rivlin, J., Hoffstein, V., Kalbfleisch, J., McNicholas, W., Zamel, N. and Bryan, A. C. Upper airway morphology in patients with idiopathic obstructive sleep apnea. Am. Rev. Respir. Dis., 1984, 129: 355–360.
- Shahar, E., Whitney, C. W., Redline, S., Lee, E. T., Newman, A. B., Javier Nieto, F., O'Connor, G. T., Boland, L. L., Schwartz, J. E. and Samet, J. M. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med., 2001, 163: 19–25.
- Stradling, J., Smith, D., Radulovacki, M. and Carley, D. Effect of ondansetron on moderate obstructive sleep apnoea, a single night, placebo-controlled trial. J. Sleep Res., 2003, 12: 169–170.
-
Veasey, S.
Pharmacotherapeutic trials for sleep-disordered breathing. In: A. I. Pack (ed.) Sleep Apnea: Pathogenesis, Diagnosis, and Treatment. Marcel Dekker Inc., New York, 2002: 607–622.
10.1201/b14008-22 Google Scholar
- Veasey, S. C., Chachkes, J., Fenik, P. and Hendricks, J. C. The effects of ondansetron on sleep-disordered breathing in the English bulldog. Sleep, 2001, 24: 155–160.
- Vitagliano, S., Berrino, L., Pizzirusso, A., D'Amico, M., Calderaro, V., Maione, S. and Rossi, F. Metabotropic glutamate receptors are involved in the control of breathing at the medulla oblongata level of anaesthetized rats. Neuropharmacology, 1994, 33: 859–864.
- Wilcox, I., Collins, F. L., Grunstein, R. R., Hedner, J., Kelly, D. T. and Sullivan, C. E. Relationship between chemosensitivity, obesity and blood pressure in obstructive sleep apnoea. Blood Press, 1994, 3: 47–54.
- Younes, M., Ostrowski, M., Thompson, W., Leslie, C. and Shewchuk, W. Chemical control stability in patients with obstructive sleep apnea. Am. J. Respir. Crit. Care Med., 2001, 163: 1181–1190.
- Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S. and Badr, S. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med., 1993, 328: 1230–1235.
Citing Literature
